메뉴 건너뛰기




Volumn 65, Issue 4, 2016, Pages 741-747

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

(12)  Cheung, Michelle C M a   Walker, Alex J b   Hudson, Benjamin E c   Verma, Suman d   McLauchlan, John e   Mutimer, David J f   Brown, Ashley g   Gelson, William T H h   MacDonald, Douglas C i   Agarwal, Kosh d   Foster, Graham R j   Irving, William L k  


Author keywords

Daclatasvir; Decompensated cirrhosis; Hepatitis C virus; Ledipasvir; MELD score; Sofosbuvir

Indexed keywords

DACLATASVIR; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

EID: 84979533481     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.06.019     Document Type: Article
Times cited : (347)

References (15)
  • 1
    • 84938953785 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
    • [1] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
    • (2015) Gastroenterology , vol.149 , pp. 649-659
    • Charlton, M.1    Everson, G.T.2    Flamm, S.L.3    Kumar, P.4    Landis, C.5    Brown, R.S.6
  • 2
    • 84952931354 scopus 로고    scopus 로고
    • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
    • [2] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
    • (2015) N Engl J Med , vol.373 , pp. 2618-2628
    • Curry, M.P.1    O'Leary, J.G.2    Bzowej, N.3    Muir, A.J.4    Korenblat, K.M.5    Fenkel, J.M.6
  • 3
    • 84991532636 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme European association for the study of the liver
    • The International Liver Congress Barcelona, Spain
    • [3] Leroy, V., Hezode, C., Metivier, S., Tateo, M., Conti, F., Nguyen-Khac, E., et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme European association for the study of the liver. 2016, The International Liver Congress, Barcelona, Spain.
    • (2016)
    • Leroy, V.1    Hezode, C.2    Metivier, S.3    Tateo, M.4    Conti, F.5    Nguyen-Khac, E.6
  • 4
    • 84991561168 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: results of a European Multicentre Compassionate Use Programme. European Association for the Study of the Liver
    • The International Liver Congress Barcelona, Spain
    • [4] Petersen, J., Welzel, T., Herzer, K., Ferenci, P., Gschwantler, M., Cornberg, M., et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: results of a European Multicentre Compassionate Use Programme. European Association for the Study of the Liver. 2016, The International Liver Congress, Barcelona, Spain.
    • (2016)
    • Petersen, J.1    Welzel, T.2    Herzer, K.3    Ferenci, P.4    Gschwantler, M.5    Cornberg, M.6
  • 5
    • 84991593714 scopus 로고    scopus 로고
    • Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution
    • [5] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
    • (2016) J Hepatol , vol.65 , pp. 719-726
    • Reig, M.1    Mariño, Z.2    Perelló, C.3    Iñarrairaegui, M.4    Ribeiro, A.5    Lens, S.6
  • 6
    • 84991568756 scopus 로고    scopus 로고
    • Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. European Association for the Study of the Liver
    • The International Liver Congress Barcelona, Spain
    • [6] Buonfiglioli, F., Conti, F., Andreone, P., Crespi, C., Foschi, G., Lenzi, M., et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. European Association for the Study of the Liver. 2016, The International Liver Congress, Barcelona, Spain.
    • (2016)
    • Buonfiglioli, F.1    Conti, F.2    Andreone, P.3    Crespi, C.4    Foschi, G.5    Lenzi, M.6
  • 7
    • 0036242165 scopus 로고    scopus 로고
    • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    • [7] Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002), 1303–1313.
    • (2002) Gastroenterology , vol.122 , pp. 1303-1313
    • Poynard, T.1    McHutchison, J.2    Manns, M.3    Trepo, C.4    Lindsay, K.5    Goodman, Z.6
  • 8
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • [8] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3    Wedemeyer, H.4    Dufour, J.F.5    Lammert, F.6
  • 9
    • 19944428400 scopus 로고    scopus 로고
    • Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival
    • [9] Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005), 105–114.
    • (2005) Ann Intern Med , vol.142 , pp. 105-114
    • Shiratori, Y.1    Ito, Y.2    Yokosuka, O.3    Imazeki, F.4    Nakata, R.5    Tanaka, N.6
  • 10
    • 33947360829 scopus 로고    scopus 로고
    • Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    • [10] Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnù, L., Mazzella, G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
    • (2007) Hepatology , vol.45 , pp. 579-587
    • Bruno, S.1    Stroffolini, T.2    Colombo, M.3    Bollani, S.4    Benvegnù, L.5    Mazzella, G.6
  • 11
    • 84931560807 scopus 로고    scopus 로고
    • Liver EAfSo. EASL recommendations on treatment of hepatitis C 2015
    • [11] Liver EAfSo. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
    • (2015) J Hepatol , vol.63 , pp. 199-236
  • 12
    • 84939653819 scopus 로고    scopus 로고
    • Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
    • [12] Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
    • (2015) Hepatology , vol.62 , pp. 932-954
  • 13
    • 84962086858 scopus 로고    scopus 로고
    • Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy
    • [13] Bunchorntavakul, C., Reddy, K.R., Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 23 (2016), 408–418.
    • (2016) J Viral Hepat , vol.23 , pp. 408-418
    • Bunchorntavakul, C.1    Reddy, K.R.2
  • 14
    • 84962847001 scopus 로고    scopus 로고
    • Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
    • [14] G.R. Foster W.L. Irving, Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
    • (2016) J Hepatol , vol.64 , pp. 1224-1231
    • Foster, B.R.1    Irving, B.L.2    Cheung, M.C.3    Walker, A.J.4    Hudson, B.E.5    Verma, S.6
  • 15
    • 79952316752 scopus 로고    scopus 로고
    • Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
    • quiz e812
    • [15] Lok, A.S., Everhart, J.E., Wright, E.C., Di Bisceglie, A.M., Kim, H.Y., Sterling, R.K., et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140 (2011), 840–849 quiz e812.
    • (2011) Gastroenterology , vol.140 , pp. 840-849
    • Lok, A.S.1    Everhart, J.E.2    Wright, E.C.3    Di Bisceglie, A.M.4    Kim, H.Y.5    Sterling, R.K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.